Vikten

[Luusje]

Riktigt duktigt, Richard!

[Geta]

Från soffpotatis till filmstjärna.

[Klankedinken]

Jag var 70 kg, nu är jag 118 kg, herrejössaness!

15 kg abilify
8 kg risperdal
30 kg zyprexa
Gick ner 20 kg under medicinuttrappning
15 kg zyprexa andra gången.

Ska vi se..
15
23
53
33
48 kg plus... och idag står jag på cirka 118 kg, har latuda som medicin och mår bra!

Det stämmer!

[Richard]

De mediciner jag haft som bidragit till att jag gått upp i vikt:
-Risperdal (risperidon)
-Seroxat (paroxetin)
-Remeron (mirtazapin)
-Zyprexa (olanzapin)
-Seroquel (quetiapin)

Men sen har det inte bara berott på mediciner, jag rör ju inte på mig så mycket.

[Klankedinken]

[amandara]

Hunk!

[memphis]

Det stämmer. Men är det inte meningen av antipsykotika att minska stress och på det sättet kortisolfrisättning?

Man kan leva i en stressande miljö.

Jag lever ett ostressat liv. Gör allt i min egen takt. Ändå har jag bukfettet. Jag tror som Luusje att antipsykotikan påverkar insulin också.

[Nobel]

Intressant läsning för den nyfikna om sambandet mellan antipsykotika och viktökning. Ett utdrag:

Second generation antipsychotics (SGAs; also known as atypical antipsychotics) are the cornerstone of schizophrenia treatment. They effectively reduce psychotic symptoms while demonstrating a reduction in extrapyramidal side effects as compared to their typical, or first generation counterparts. However, SGAs are not without their own set of common side effects. Numerous studies have linked SGAs to metabolic changes which place patients at risk for cardiovascular complications, including antipsychotic-induced weight gain (AIWG), dyslipidemia, insulin resistance and type-2 diabetes (Wirshing et al., 1998; Allison and Casey, 2001; Nasrallah, 2003; Nasrallah and Newcomer, 2004; Mackin et al., 2005; Chiu et al., 2006; Oriot et al., 2008; Fernandez-Egea et al., 2011). Notably, patients with schizophrenia have significantly reduced lifespans compared to the general population—by 11–20 years—which is attributable to their higher risk of death from cardiovascular causes (Hennekens and Newcomer, 2007; Laursen et al., 2013; Kredentser et al., 2014).

The metabolic liability differs among agents, with clozapine (CLZ), and olanzapine (OLZ), representing the two SGAs with the most adverse metabolic profile. Despite differences among agents, even the SGAs considered to be most metabolically neutral, (e.g., ziprasidone, and aripiprazole), are associated with significant weight gain in antipsychotic antipsychotic-naïve individuals (Correll, 2009; Patel et al., 2009; Bak et al., 2014). Moreover, CLZ represents the sole antipsychotic with superiority in treatment refractory schizophrenia, with some evidence also supporting efficacy advantages for OLZ, precluding avoidance of these agents in severely ill individuals (Lieberman et al., 2005). Therefore, with existing antipsychotics, early and effective treatment of schizophrenia is associated with an increase in cardiovascular burden.

Despite the associated cardio-metabolic morbidity, the underlying causes of AIWG and other metabolic changes remain largely elusive. Increased food intake appears to be a component (Benarroch et al., 2016), although it is less clear if AIWG is also attributable to reductions in resting energy expenditure (Cuerda et al., 2013). Animal and some human studies show that the various areas of neurotransmission altered by antipsychotics may affect energy and glucose regulation (Hahn et al., 2011). Antagonism of the histamine H1 (H1), serotonin 2A/2C (5-HT2A/C), and dopamine D1/D2/D3 receptors, as well as, adrenergic and muscarinic receptors are common effects of antipsychotics and each receptor has been implicated in weight regulation (Roerig et al., 2011). Similarly, disruption of insulin homeostasis has been tied to antagonism of serotonergic (5-HT2A/C) (Nonogaki et al., 1998; Gilles et al., 2005; Tulipano et al., 2007; Hahn et al., 2011; Guenette et al., 2013), adrenergic (α1) (Zillich et al., 2006; Savoy et al., 2008; Guenette et al., 2013) and muscarinic (M3) receptors (Hahn et al., 2011), both via the peripheral and central nervous system (CNS). Taken together, the possibility exists that neurotransmitter systems implicated in energy homeostasis may overlap with those implicated in therapeutic action of antipsychotics.

Raben, Alex T et al. “The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.” Frontiers in neuroscience vol. 11 741. 22 Jan. 2018, doi:10.3389/fnins.2017.00741

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5786866/

[Swesanne]

Det finns artiklar som visar att Metformin påverkar så att Olanzapin inte ska påverka vikten. Jag har fått det, men har inte diabetes. Kanske det hjälpt lite iaf…
Gått upp 12 kg på 5 år

[zoegas]

Piller har 0 kalorier. Ni vet detta.

[Luusje]

Tack, Nobel! Superintressant artikel.

[wasp]

Tack, Nobel! Superintressant artikel.

Säger detsamma! Håller min vikt trots Risperdal, 78,8 kg imorse och 177cm lång.